ABIOMED (ABMD) Earns Daily Coverage Optimism Score of 0.19
News headlines about ABIOMED (NASDAQ:ABMD) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ABIOMED earned a news impact score of 0.19 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 46.2833198397854 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of ABIOMED (ABMD) traded down $1.21 during trading hours on Monday, reaching $237.68. The company’s stock had a trading volume of 82,198 shares, compared to its average volume of 274,634. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.84 and a quick ratio of 5.20. ABIOMED has a 12 month low of $103.53 and a 12 month high of $239.92. The firm has a market capitalization of $10,562.79, a price-to-earnings ratio of 117.68, a PEG ratio of 3.15 and a beta of 0.15.
ABMD has been the subject of several analyst reports. Zacks Investment Research upgraded ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 target price for the company in a research note on Tuesday, November 7th. SunTrust Banks restated a “buy” rating and set a $195.00 price target on shares of ABIOMED in a research note on Wednesday, November 1st. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Piper Jaffray Companies restated a “buy” rating on shares of ABIOMED in a research note on Thursday, January 4th. Finally, Jefferies Group upped their price target on ABIOMED from $208.00 to $220.00 and gave the stock a “buy” rating in a research note on Thursday, December 21st. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $210.50.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.